Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

Research output: Contribution to journalArticleAcademicpeer-review

37 Citations (Scopus)


Natalizumab is frequently used as a treatment for multiple sclerosis (MS). The occurrence of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients indicates that its prominent beneficial effects need to be balanced against the risks. Also, cessation of the drug seems to be associated with recurrence of disease activity. Both the moment of rebound disease activity and the outcome of PML are related to clearance of the drug. Specific features of this IgG4 antibody (i.e. half-antibody exchange) may result in underestimated drug levels. Here, we demonstrate natalizumab levels in 10 patients with relapsing MS, using a recently developed sensitive assay. Remarkably, natalizumab was detectable up to 200 days after cessation of therapy
Original languageEnglish
Pages (from-to)899-901
Issue number6
Publication statusPublished - 2012

Cite this